| Identification | Back Directory | [Name]
AZD-0284 | [CAS]
2101291-07-8 | [Synonyms]
AZD-0284
(1R)-2-acetyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-methanesulfonyl-2,3-dihydro-1H-isoindole-1-carboxamide
1H-Isoindole-1-carboxamide, 2-acetyl-2,3-dihydro-5-(methylsulfonyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-, (1R)- | [Molecular Formula]
C21H18F6N2O5S | [MDL Number]
MFCD31813716 | [MOL File]
2101291-07-8.mol | [Molecular Weight]
524.43 |
| Chemical Properties | Back Directory | [Boiling point ]
731.9±60.0 °C(Predicted) | [density ]
1.534±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 100 mg/mL (190.68 mM) | [form ]
Solid | [pka]
9.26±0.15(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
AZD-0284 is a selective inverse agonist of the nuclear receptor RORγ. AZD-0284 has the potential for plaque psoriasis vulgaris and respiratory tract disorders treatment[1]. | [References]
[1] Narjes, F, et al. The discovery of AZD0284, an inverse agonist of the nuclear receptor RORg. American Chemical Society, 2017 Drug Design and Delivery Symposium 26 October 2017
[2] Asimus S, et al. Pharmacokinetics, pharmacodynamics and safety of the inverse retinoic acid-related orphan receptor γ agonist AZD0284 [published online ahead of print, 2020 Feb 17]. Br J Clin Pharmacol. 2020;10.1111/bcp.14253. DOI:10.1111/bcp.14253 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|